創薬アウトソーシング市場レポート：2030年までの動向、予測、競合分析

創薬アウトソーシングの動向と予測

世界の創薬アウトソーシング市場は、2024年から2030年までのCAGRが7.2%で、2030年までに推定61億米ドルに達すると予想されます。この市場の主な促進要因は、創薬研究における共同研究の世界の傾向の高まり、遺伝性疾患、代謝性疾患、その他の慢性疾患の罹患率の上昇、創薬技術の向上、トップクラスのバイオテクノロジー企業と製薬企業の大きな存在感などです。世界の創薬アウトソーシング市場の将来は、製薬会社やバイオテクノロジー企業、学術研究機関の市場に機会があり、有望視されています。

• Lucintelの予測によると、薬剤の種類別では、低分子が予測期間中も引き続き大きな割合を占める。これは、創薬のためのバイオ医薬品研究と技術の急速な進歩に加え、経口投与が可能であること、細胞膜を通過して細胞内の標的に到達するため高分子に比べて精度が高いことなどの明確な利点があるためです。
• 最終用途のカテゴリーでは、製薬・バイオテクノロジー企業がパイプライン治療薬の増加率に加え、製薬・バイオ医薬品企業の研究開発費の増加により、より高い成長が見込まれています。
• 地域別では、技術的に高度なAIベースの創薬システムの高い採用率、ヘルスケア支出の増加、がんや慢性疾患を治療するための新規薬理学的治療法の創出のためのアウトソーシングサービスを提供する重要な主要企業の同国での存在により、北米が予測期間中に最も高い成長を示すと予想されます。

創薬アウトソーシング市場の戦略的成長機会

創薬アウトソーシング市場は、進化する業界のニーズを反映し、専門的なアウトソーシングサービスを求めるさまざまなアプリケーションに、数多くの戦略的成長機会をもたらしています。

• ゲノムおよびバイオインフォマティクスサービスの拡大：創薬におけるゲノムとバイオインフォマティクスの重要性の高まりは、これらの分野に特化したアウトソーシングの機会を提供しています。ゲノミクスとバイオインフォマティクスに対応するサービスを拡大することで、標的治療の開発をサポートし、創薬のスピードアップを図ることができます。この機会はプレシジョンメディシンのトレンドと合致し、アウトソーシングパートナーの能力を拡大します。
• 臨床試験アウトソーシングの成長：臨床試験の複雑性とコストの増大は、臨床試験管理・実施サービスのアウトソーシング需要を促進しています。このような臨床試験アウトソーシングの成長により、CROはサービス内容や専門性を拡大する機会を得ています。この動向は、より効率的で費用対効果の高い臨床試験をサポートし、製薬企業とアウトソーサーの双方に利益をもたらします。
• 個別化医療ソリューションへの需要の高まり：個別化医療に焦点を当てることで、オーダーメイドの治療法や治療法の開発を促進するアウトソーシングサービスの可能性が広がります。個別化医療ソリューションに対する要求の高まりは、医薬品のカスタマイズを促進する特定のサービスに対する需要を生み出します。これは、企業内での新薬発見のプロセス全体を通じて、より正確で効率的な治療へのシフトと一致しています。
• 新興市場への投資の増加：インドや中国のような新興市場への投資は、コスト面で優位性があり、研究能力が高まっている地域に創薬活動をアウトソースする機会を提供します。新興市場におけるCROやCDMOサービスの拡大は、これらの地域への投資の増加によって支えられています。この機会は、製薬会社の開発コストを削減しながら、創薬活動を世界化するのに役立ちます。
• AIと機械学習技術の進歩：創薬における人工知能（AI）と機械学習（ML）技術の統合は、アウトソーシング・パートナーに高度なデータ分析と医薬品開発サービスを提供する機会を提供します。AIとML技術による効率的な創薬は、重要なイノベーションの推進力となります。この機会は、アウトソーシングパートナーの能力を高め、新しい治療法の開発を迅速に進める。

創薬アウトソーシング市場はダイナミックであり、さまざまな用途で多くの成長機会があります。早期段階の創薬やスクリーニング、前臨床試験や毒性試験、臨床試験管理、バイオマーカー探索、データ分析など、アウトソーシングが大きなメリットをもたらす分野は数多くあります。このような機会を活用することで、製薬会社は特定の専門分野における専門的なスキルや知識を活用し、先進技術に世界にアクセスすることで、比較的低コストで新薬開発に関連するプロセスを合理化することができます。そのため、アウトソーシングは創薬エコシステムにとって不可欠な要素になりつつあり、このようなパターンが市場を変革し続ける中で、イノベーションによる新治療法の迅速な開発がもたらされています。

創薬アウトソーシング市場の促進要因・課題

創薬アウトソーシング市場の成長に影響を与える市場促進要因・課題はいくつかあります。これらには、技術的ブレークスルー、経済状況、規制要件などの要因が含まれます。

創薬アウトソーシング市場を牽引する要因としては、以下のようなものが挙げられる：

1.技術の進歩：人工知能（AI）、ゲノミクス、バイオインフォマティクスなどの技術革新が創薬方法を変え、市場の成長を促進しています。技術の進歩により、製薬会社はリード分子へとさらに最適化できる新規の分子実体を特定できるようになった。このような理解は、臨床試験のアウトソーシングへの依存を刺激し、CRO内の専門アウトソーシング施設やこの分野で同様のサービスを提供する企業の利用を増加させています。

2.医薬品開発の複雑化：医薬品開発プロセスの複雑化に伴い、創薬の様々な段階において専門的なアウトソーシングサポートが必要とされています。新しいバイオ医薬品の発見に伴う複雑さは、従来の垂直統合モデルから、製造受託機関（CMO）、初期段階の開発に携わる学術機関の研究開発部門のような研究ベースのサービスプロバイダー、開発業務受託機関（CRO）、バイオテクノロジー企業など、それぞれが1つ以上の第三者別管理される多数の専門分野を包含する水平サプライチェーンネットワークへの転換を促しています。

3.コスト効率とリソースの最適化：創薬アウトソーシングにより、製薬企業は外部の専門知識を活用することで、コストを削減し、リソースを節約することができます。創薬プロセスを加速させる費用対効果の高い戦略として、臨床試験の様々なフェーズをアウトソーシングすることが挙げられます。これにより、重複を避け、製薬業界内でより高い品質レベルを達成することでコストを削減することができます。この戦略により、企業は自社のコアコンピタンスに集中できる一方、研究開発プロセスのどの段階においても、長年の経験を持つ第三者からの支援を受けることができる（Valiunas &Naulickaite, 2011）。

4.新興市場への進出：新興市場における製薬産業の成長は、競争力のあるコスト構造を持つ地域に創薬活動をアウトソーシングする機会を提供します。過去10年間、中国には数多くの多国籍製薬企業が進出しており、低い運営コスト、有利な規制の枠組み、税制優遇措置、インセンティブなどの恩恵を受けています。これらの国々の市場の魅力は、先進国に比べて労働賃金が低いこと別生産コストの低さ、規制や規模の経済などの参入障壁が低いことによる市場へのアクセスの容易さなど、いくつかの要因によって決定されます。

5.個別化医療への注力：個別化治療や標的治療別個別化医療を対象としたアウトソーシング・サービスのニーズが高まっています。患者固有の疾患変異に合わせた薬剤に対する需要の高まりにより、前臨床試験中の患者層別化のためのバイオマーカーの利用が増加しています。この促進要因は、新たな研究リソースへのアクセスやコスト面でのメリットをもたらし、市場拡大に寄与しています。

創薬アウトソーシング市場の課題は以下の通りである：

1.規制コンプライアンスと品質基準：アウトソーシング先が規制を遵守することは難しく、コストもかかります。アウトソーシング・ベンダーが直面する課題には、米国FDA、ISO、MHRAなどの各種規制機関が定める品質および規制要件への適合が含まれます。さらに、顧客の資金を効率的に活用し、時間通りにサービスを提供し、その方法が合意に合致していることを確認しなければならないです。この課題には、業界のあらゆるルールを厳格に遵守し、市場の受容を確保するための効果的なマネジメントが求められる（Benedetto et al.）

2.知的財産に関する懸念：データの機密性とセキュリティの問題が高まっているため、アウトソーシング契約における知的財産（IP）の保護が懸念されています。知的財産権は、これらの保護を明確に認めています。強固なセキュリティ対策と法的契約別これらの懸念に対処することは、信頼を維持し、貴重な知的財産を保護するために不可欠です。

3.グローバルパートナーシップの管理：グローバルパートナーシップを管理し、様々な地域にまたがる活動を調整することは複雑で課題です。グローバルパートナーシップを効果的に管理することは、新薬の創製を成功させるために不可欠です。この課題には、地域や物流の壁を乗り越えるだけでなく、強力なコミュニケーションと調整が必要です。

創薬アウトソーシング市場は様々な要因に後押しされ、複数の課題に直面しています。技術開拓、医薬品開発プロセスの複雑化、費用対効果、新興国市場への参入、個別化医療などが市場成長に寄与しています。しかし、規制への対応、知的財産権に関する懸念、世界なパートナーシップの管理といった課題も依然として残っています。これらの促進要因・課題に効率的に対処することで、アウトソーシングパートナーは機会を活用し、リスクを低減し、革新的ソリューションの市場開拓を促進することができ、市場全体の成長を高めることができます。

目次

第1章 エグゼクティブサマリー

第2章 世界の創薬アウトソーシング市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の創薬アウトソーシング市場の動向（2018～2023年）と予測（2024～2030年）
• 医薬品タイプ別：世界の創薬アウトソーシング市場
  • 低分子
  • 大分子
• ワークフロー別：世界の創薬アウトソーシング市場
  • ターゲットの特定とスクリーニング
  • ターゲット検証と機能情報学
  • リードの特定と候補者の最適化
  • 前臨床開発
  • その他の関連ワークフロー
• 治療領域別：世界の創薬アウトソーシング市場
  • 心臓血管
  • 中枢神経系（CNS）
  • 胃腸
  • 血液学
  • 呼吸器系
  • 感染症
  • 腫瘍学
  • 免疫学
  • その他
• 最終用途別：世界の創薬アウトソーシング市場
  • 製薬・バイオテクノロジー企業
  • 学術機関
  • その他

第4章 2018年から2030年までの地域別市場動向と予測分析

• 地域別世界創薬アウトソーシング市場
• 北米の創薬アウトソーシング市場
• 欧州の創薬アウトソーシング市場
• アジア太平洋地域の創薬アウトソーシング市場
• その他地域医薬品の創薬アウトソーシング市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 医薬品タイプ別：世界の創薬アウトソーシング市場の成長機会
  • ワークフロー別：世界の創薬アウトソーシング市場の成長機会
  • 治療領域別：世界の創薬アウトソーシング市場の成長機会
  • 最終用途別：世界の創薬アウトソーシング市場の成長機会
  • 地域別：世界の創薬アウトソーシング市場の成長機会
• 世界の創薬アウトソーシング市場の新たな動向
• 戦略分析
  • 新製品開発
  • 世界の創薬アウトソーシング市場のキャパシティ拡大
  • 世界の創薬アウトソーシング市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Albany Molecular Research
• EVOTEC
• GenScript
• Pharmaceutical Product Development
• Charles River
• WuXi AppTec
• Merck & Co
• Thermo Fisher Scientific
• Dalton Pharma Services
• Oncodesign

Drug Discovery Outsourcing Trends and Forecast

The future of the global drug discovery outsourcing market looks promising with opportunities in the pharmaceutical and biotechnology company and academic institute markets. The global drug discovery outsourcing market is expected to reach an estimated $6.1 billion by 2030 with a CAGR of 7.2% from 2024 to 2030. The major drivers for this market are the increasing global trend of collaborations in drug discovery research, rising rates of genetic, metabolic, and other chronic illnesses, as well as improvements in drug discovery technologies, and the significant presence of top biotechnology and pharmaceutical firms.

• Lucintel forecasts that, within the drug type category, small molecules will remain a larger segment over the forecast period due to the rapid advancement of biopharmaceutical research and technology for the discovery and some distinct advantages, such as it can be administered orally and pass through cell membranes to reach intracellular targets more precisely as compared to large molecules.
• Within the end-use category, pharmaceutical and biotechnology companies are expected to witness higher growth due to the growing rate of pipeline therapeutics, along with the pharmaceutical and biopharmaceutical firms' increasing R&D spending.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to the high adoption rate of technologically advanced AI-based drug discovery systems, increase in healthcare expenditure, and presence of significant key firms in the country providing outsourcing services for the creation of novel pharmacological therapies to treat cancer and chronic diseases.

Gain valuable insight for your business decisions with our comprehensive 150+ page report

Emerging Trends in the Drug Discovery Outsourcing Market

The drug discovery outsourcing market is undergoing significant changes due to emerging trends that will shape its future. These trends have arisen from advancements in technology, shifting industry requirements, and more complex processes in drug discovery.

• Artificial Intelligence (AI) & Machine Learning (ML) Integration: AI and ML are increasingly being integrated into the drug discovery process for better data analysis, predicting drug interactions, and optimizing development. The application of AI/ML hastens drug discovery, shortening time frames and reducing costs while increasing accuracy. This trend helps develop much more efficient pipelines for drug development, ensuring accurate identification of novel therapeutic agents.
• Precision Medicine Emergence: There is an increasing focus on precision medicine, where specific genetic profiles or patient populations inform decisions involving the discovery and development of medications. It enhances efficacy while minimizing adverse reactions through personalized therapies. Moreover, this trend leads to a higher demand for specialized outsourcing services that can support precision drug development and clinical trials.
• Wider Use of Advanced Genomics and Bioinformatics: Advanced genomics and bioinformatics are used to analyze complex biological information, expediting the pace at which new drugs are discovered. This integration assists in understanding disease mechanisms and identifying new drug targets more effectively. Consequently, this trend facilitates the development of targeted therapies and advances the entire process of creating innovative drugs.
• The Growing Outsourcing of Clinical Trials: There is a rising trend of outsourcing clinical trials to contract research organizations (CROs) instead of conducting them in-house, allowing pharmaceutical firms to concentrate on their core competencies and remain competitive. By offshoring, these companies access specialized expertise at lower costs and reduce their time-to-market. This also contributes to growth in the CRO market, coupled with innovative trial management and execution.
• Increasing Focus on New Markets: Drug discovery activities are being transferred by pharmaceutical companies to emerging markets like India and China due to lower costs and increasing research capabilities. The emphasis on new markets leads to greater availability of research resources while minimizing development expenditures. As a result, this drives the expansion of CRO and contract development and manufacturing organization (CDMO) services into these areas, supporting global integration in drug discovery.

The drug discovery outsourcing market is witnessing several trends that are reshaping it. Among these are the integration of AI and ML, a focus on precision medicine, growth in clinical trial outsourcing, expansion into emerging markets, and an increased emphasis on data integration and real-world evidence (RWE). These trends promote innovation, boost efficiency, and broaden the scope of activities for CROs. Pharmaceutical firms and CROs that have adopted advanced technologies and new collaboration platforms have managed to navigate the complexities of drug development more effectively, resulting in better patient outcomes and increased success in drug discovery.

Recent Developments in the Drug Discovery Outsourcing Market

There have been significant developments in the drug discovery outsourcing market, indicating technological advancements, changing industry needs, and shifts in market dynamics.

• AI-Driven Drug Discovery Advancements: The integration of AI technologies is currently revolutionizing the industry by improving data analysis and speeding up drug development. AI-driven approaches enhance the efficacy of drug discovery pipelines, reduce the time to identify potential drug candidates, and lower development costs. This development facilitates the production of more focused and effective therapies.
• Growth in CRO Services across Emerging Markets: Contract research organizations (CROs) have been expanding their services into emerging markets like India and China as they seek to exploit cost advantages and growing research capabilities. The expansion into emerging markets provides pharmaceutical companies with access to a wider range of services while also lowering developmental costs. This move supports global outsourcing trends and enhances the capabilities of CROs in these regions.
• Increased Collaborations between Academia and Industry: Collaboration between academic institutions and pharmaceutical firms is increasing for innovation in drug discovery. Academic partnerships provide access to cutting-edge research and technologies, facilitating the development of novel drug candidates. This collaboration enhances the overall process of drug discovery and contributes to advancements in scientific knowledge.
• An Increase in Personalized Medicine Initiatives: Personalized medicine has become increasingly important because it focuses on tailoring drugs for individual patient profiles during discovery and development. Such initiatives stimulate demand for specialized outsourcing services that can support the creation of targeted therapies. This aligns with the shift toward more precise and efficient treatments.
• Strengthened Regulatory Support and Compliance: There is an increasing emphasis on streamlining processes to ensure compliance in regulatory environments for improving drug discovery and development. Faster and more efficient regulations contribute to rapid drug development, which shortens new therapy launch periods. Thus, it conforms to general growth and efficiency standards within the market for outsourced operations related to drug discovery.

The industry is currently experiencing a significant impact from recent developments in the drug discovery outsourcing market. The efficiency of drug discovery is improved by the introduction of AI and ML, while emerging markets serve as reliable sources of cost-efficient and resource-abundant solutions. Clinical trial methodologies are also evolving as virtual and decentralized trials gain popularity, and personalized medicine shifts focus toward tailored therapeutic approaches. Furthermore, real-world evidence (RWE) integration is providing insights into real-world drug performance. Overall, these developments are reshaping the landscape of drug discovery, propelling innovation and augmenting the abilities of outsourcing partners to meet the constantly changing requirements of the pharmaceutical sector.

Strategic Growth Opportunities for Drug Discovery Outsourcing Market

The market for outsourcing in drug discovery presents numerous strategic opportunities for growth across different applications, reflecting evolving industry needs and calling for specialized outsourcing services.

• Expansion of Genomic and Bioinformatics Services: The growing importance of genomics and bioinformatics in drug discovery offers opportunities for specialized outsourcing in these areas. Broadening services to accommodate genomics and bioinformatics supports targeted therapy development and speeds up drug discovery. This opportunity aligns with the precision medicine trend, expanding the capabilities of outsourcing partners.
• Growth in Clinical Trial Outsourcing: The increased complexity and cost of clinical trials are driving demand for outsourced clinical trial management and execution services. This growth in clinical trial outsourcing creates opportunities for CROs to expand their service offerings and expertise. This trend supports more efficient and cost-effective clinical trials, benefiting both pharmaceutical companies and their outsourcers.
• Increasing Demand for Personalized Medicine Solutions: Focusing on personalized medicine opens up possibilities for service outsourcing that fosters the creation of bespoke therapies or treatments. Growing requirements for personalized medicine solutions create a demand for specific services that can facilitate the customization of drugs. This aligns with the shift toward more precise and efficient treatments throughout the entire process of discovering new drugs within a company setting.
• Increased Investments in Emerging Markets: Investments in emerging markets like India and China provide opportunities to outsource drug discovery activities to regions with cost advantages and growing research capabilities. The expansion of CRO and CDMO services in emerging markets is supported by increased investment in these regions. This opportunity helps to globalize drug discovery efforts while reducing development costs for pharmaceutical companies.
• Advancements in AI and Machine Learning Technologies: The integration of Artificial Intelligence (AI) and Machine Learning (ML) technologies in drug discovery provides opportunities for outsourcing partners to deliver advanced data analysis and drug development services. Efficient drug discovery through AI and ML technology serves as a key innovation driver. This opportunity enhances the capabilities of outsourcing partners and fast-tracks the development of new therapies.

The drug discovery outsourcing market is dynamic, with many opportunities for growth in different applications. There are numerous areas where outsourcing can provide significant advantages, such as early-stage drug discovery and screening, preclinical and toxicology studies, clinical trial management, biomarker discovery, and data analytics. Such opportunities allow pharmaceutical companies to leverage specialized skills and knowledge in specific areas of expertise, as well as access advanced technologies globally, to streamline processes related to the development of new drugs at relatively lower costs. Outsourcing is therefore becoming an essential component of the drug discovery ecosystem, resulting in faster development of new therapies through innovation as these patterns continue to transform the market.

Drug Discovery Outsourcing Market Driver and Challenges

There are several drivers and challenges influencing the growth of the drug discovery outsourcing market. These include factors such as technological breakthroughs, economic conditions, and regulatory requirements.

The factors responsible for driving the drug discovery outsourcing market include:

1. Technological Advances: Innovations such as artificial intelligence (AI), genomics, and bioinformatics are changing how drugs are discovered, thereby driving market growth. Technological advancements enable pharmaceutical firms to identify novel molecular entities that can be further optimized into lead molecules. Such understanding has stimulated reliance on outsourced clinical trials, increasing the use of specialized outsourcing facilities within CROs or companies offering similar services in this sector.

2. Increasing Complexity of Drug Development: The increasing complexity of drug development processes has necessitated specialized outsourcing support across various stages of discovery. The complexity associated with discovering a new biopharmaceutical product has facilitated the transformation from traditional vertical integration models to horizontal supply chain networks that encompass numerous specializations, each managed by one or more third parties, such as contract manufacturing organizations (CMOs), research-based service providers like R&D departments within academic institutions involved in early-stage development, contract research organizations (CROs), and biotechnology firms.

3. Cost Efficiency and Resource Optimization: By outsourcing drug discovery, pharmaceutical companies can cut costs and save resources by utilizing external expertise. One cost-effective strategy that helps accelerate the drug discovery process is outsourcing various phases of clinical trials; this saves costs by avoiding duplication and achieving a higher level of quality within the pharmaceutical industry. This strategy allows companies to concentrate on their core competencies while receiving assistance from third parties with many years of experience at any stage of the R&D process (Valiunas & Naulickaite, 2011).

4. Expansion into Emerging Markets: The growth of pharmaceutical industries in emerging markets provides opportunities for outsourcing drug discovery activities to regions with competitive cost structures. Over the past decade, China has attracted numerous multinational pharmaceutical corporations that have set up facilities there to benefit from lower operating costs, favorable regulatory frameworks, tax breaks, and incentives. The attractiveness of these countries' market conditions is determined by several factors, such as low production costs due to lower labor wages compared to developed countries, and easy access to these markets due to low entry barriers like regulations and economies of scale.

5. Focus on Personalized Medicine: There is an increasing need for outsourced services targeting personalized medicine through individualized treatments or targeted therapies. The growing demand for drugs tailored to patient-specific disease variants has led to increased use of biomarkers for patient stratification during preclinical testing. This driver contributes to market expansion by providing access to new research resources and cost benefits.

Challenges in the drug discovery outsourcing market include:

1. Regulatory Compliance and Quality Standards: Outsourcing partners can find it difficult and expensive to comply with the regulations that govern them. Challenges faced by outsourcing vendors include conformance to quality and regulatory requirements as stipulated by various regulatory bodies such as the FDA, ISO, and MHRA under US law. Additionally, they must efficiently utilize the customer's funds, deliver services on time, and ensure their methods align with the agreements reached. This challenge calls for effective management to ensure strict adherence to all industry rules, thereby ensuring market acceptance (Benedetto et al., 2011).

2. Intellectual Property Concerns: There are concerns about safeguarding intellectual property (IP) in outsourcing arrangements due to rising issues of data confidentiality and security. Intellectual property rights explicitly grant these protections. Addressing these concerns through robust security measures and legal agreements is essential for maintaining trust and protecting valuable IP.

3. Global Partnership Management: Managing global partnerships and coordinating their activities across various regions is complex and challenging. Effective management of global partnerships is essential for successful collaboration during the discovery of new drugs. This challenge requires strong communication and coordination, as well as overcoming regional and logistical barriers.

The drug discovery outsourcing market is driven by various factors and faces multiple challenges. Technological developments, the complexity of drug development processes, cost-effectiveness, entry into new markets, and personalized medicine contribute to market growth. However, challenges such as regulatory compliance, intellectual property concerns, and managing global partnerships persist in the industry. Efficiently addressing these drivers and challenges allows outsourcing partners to capitalize on opportunities, reduce risks, and promote the development of innovative solutions, thus enhancing overall market growth.

List of Drug Discovery Outsourcing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies drug discovery outsourcing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the drug discovery outsourcing companies profiled in this report include-

• Albany Molecular Research
• EVOTEC
• GenScript
• Pharmaceutical Product Development
• Charles River
• WuXi AppTec
• Merck & Co
• Thermo Fisher Scientific
• Dalton Pharma Services
• Oncodesign

Drug Discovery Outsourcing by Segment

The study includes a forecast for the global drug discovery outsourcing by drug type, workflow, therapeutic area, end use, and region.

Drug Discovery Outsourcing Market by Drug Type [Analysis by Value from 2018 to 2030]:

• Small Molecules
• Large Molecules

Drug Discovery Outsourcing Market by Workflow [Analysis by Value from 2018 to 2030]:

• Target Identification & Screening
• Target Validation & Functional Informatics
• Lead Identification & Candidate Optimization
• Preclinical Development
• Other Associated Workflow

Drug Discovery Outsourcing Market by Therapeutic Area [Analysis by Value from 2018 to 2030]:

• Cardiovascular
• Central Nervous System (CNS)
• Gastrointestinal
• Hematology
• Respiratory System
• Infectious Disease
• Immunology
• Others

Drug Discovery Outsourcing Market by End Use [Analysis by Value from 2018 to 2030]:

• Pharmaceutical And Biotechnology Companies
• Academic Institutes
• Others

Drug Discovery Outsourcing Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Drug Discovery Outsourcing Market

The pharmaceutical industry has seen significant change in recent years in terms of drug discovery outsourcing, driven by technological advances, changing economies, and global regulatory adjustments. Pharmaceutical and biotechnology firms outsource different stages of the drug discovery process to CROs and CDMOs. Current developments show an increased reliance on outsourcing to cut costs, improve efficiency, and speed up timelines for drug development. Key trends include the integration of advanced technologies, increasing demand for niche services, and strategic alliances between different players.

• United States: The drug discovery outsourcing market in the United States has experienced remarkable growth due to the complex nature of drug discovery as well as the need for cost-effectiveness. Notable developments include the expansion of specialized services such as bioinformatics, high-throughput screening, and clinical trial management offered by CROs and CDMOs. The US market is also seeing a rise in deals between big pharmaceutical companies and outsourcing companies, enabling them to utilize more advanced technology platforms, thereby accelerating their drug discovery processes. Regulatory pressures driving innovation within this space have resulted in several changes, thus increasing service offerings.
• China: China's growing pharmaceutical sector, along with its competitive costs, has led to the rapidly expanding drug discovery outsourcing market, including new Chinese CROs and CDMOs that cater to both domestic and international customers. Some of these advanced services include genomic sequencing and molecular biology. China is making significant investments into research infrastructure while incorporating leading-edge technologies to attract global pharmaceutical firms. Additionally, China's regulatory environment is evolving to ensure better support mechanisms for R&D and to attract foreign investment.
• Germany: Germany plays a leading role in the European pharmaceutical industry and is now experiencing great strides, especially within its drug discovery outsourcing sector. Germany-based CROs and CDMOs are emphasizing precision medicine, sophisticated analytics, and other integrated development services. Some capabilities added include high-content imaging and early-phase trials. This has attracted global pharmaceutical companies seeking reliable partners in the high-quality German outsourcing industry, thanks to Germany's regulatory environment and emphasis on research and development. The market is also witnessing increased collaboration between academic institutions and industry players to drive advancements in drug discovery.
• India: The drug discovery outsourcing market in India is growing rapidly as it offers cost advantages over other countries and has developed expertise in drug development. For example, Indian CROs and CDMOs have significantly expanded their capabilities to perform various services such as clinical trials, data management, and regulatory affairs for numerous clients. Today, India has become a major venue for anti-cancer drug discovery, among other research activities, thanks to massive investments in research infrastructure. In addition, the Indian government is implementing policies aimed at promoting the pharmaceutical industry and improving its attractiveness as a top outsourcing location, offering reasonable prices and highly qualified personnel.
• Japan: Japan has a drug discovery outsourcing market that is developing through the merging of advanced technologies and enhancing the services it offers, such as the expansion of Japanese CROs and CDMOs into global markets to provide specialized services like biomarker discovery and clinical trial management. At the same time, Japan is focusing on building innovative drug discovery platforms and collaborating with foreign pharmaceutical companies. In this context, Japan's strict regulatory regime and its focus on high-quality research are contributing to its expanding role in the global outsourcing market. The country's market is also characterized by precision and high standards followed during drug development.

Features of the Global Drug Discovery Outsourcing Market

Market Size Estimates: Drug discovery outsourcing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Drug discovery outsourcing market size by drug type, workflow, therapeutic area, end use, and region in terms of value ($B).

Regional Analysis: Drug discovery outsourcing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug type, workflow, therapeutic area, end use, and regions for the drug discovery outsourcing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the drug discovery outsourcing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the drug discovery outsourcing market by drug type (small molecules and large molecules), workflow (target identification & screening, target validation & functional informatics, lead identification & candidate optimization, preclinical development, and other associated workflow), therapeutic area (cardiovascular, central nervous system (CNS), gastrointestinal, hematology, respiratory system, infectious disease, oncology, immunology, and others), end use (pharmaceutical and biotechnology companies, academic institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Drug Discovery Outsourcing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Drug Discovery Outsourcing Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Drug Discovery Outsourcing Market by Drug Type
  • 3.3.1: Small Molecules
  • 3.3.2: Large Molecules
• 3.4: Global Drug Discovery Outsourcing Market by Workflow
  • 3.4.1: Target Identification & Screening
  • 3.4.2: Target Validation & Functional Informatics
  • 3.4.3: Lead Identification & Candidate Optimization
  • 3.4.4: Preclinical Development
  • 3.4.5: Other Associated Workflow
• 3.5: Global Drug Discovery Outsourcing Market by Therapeutic Area
  • 3.5.1: Cardiovascular
  • 3.5.2: Central Nervous System (CNS)
  • 3.5.3: Gastrointestinal
  • 3.5.4: Hematology
  • 3.5.5: Respiratory system
  • 3.5.6: Infectious disease
  • 3.5.7: Oncology
  • 3.5.8: Immunology
  • 3.5.9: Others
• 3.6: Global Drug Discovery Outsourcing Market by End Use
  • 3.6.1: Pharmaceutical and Biotechnology Companies
  • 3.6.2: Academic Institutes
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Drug Discovery Outsourcing Market by Region
• 4.2: North American Drug Discovery Outsourcing Market
  • 4.2.1: North American Drug Discovery Outsourcing Market by Drug Type: Small Molecules and Large Molecules
  • 4.2.2: North American Drug Discovery Outsourcing Market by End Use: Pharmaceutical and Biotechnology Companies, Academic Institutes, and Others
• 4.3: European Drug Discovery Outsourcing Market
  • 4.3.1: European Drug Discovery Outsourcing Market by Drug Type: Small Molecules and Large Molecules
  • 4.3.2: European Drug Discovery Outsourcing Market by End Use: Pharmaceutical and Biotechnology Companies, Academic Institutes, and Others
• 4.4: APAC Drug Discovery Outsourcing Market
  • 4.4.1: APAC Drug Discovery Outsourcing Market by Drug Type: Small Molecules and Large Molecules
  • 4.4.2: APAC Drug Discovery Outsourcing Market by End Use: Pharmaceutical and Biotechnology Companies, Academic Institutes, and Others
• 4.5: ROW Drug Discovery Outsourcing Market
  • 4.5.1: ROW Drug Discovery Outsourcing Market by Drug Type: Small Molecules and Large Molecules
  • 4.5.2: ROW Drug Discovery Outsourcing Market by End Use: Pharmaceutical and Biotechnology Companies, Academic Institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Drug Discovery Outsourcing Market by Drug Type
  • 6.1.2: Growth Opportunities for the Global Drug Discovery Outsourcing Market by Workflow
  • 6.1.3: Growth Opportunities for the Global Drug Discovery Outsourcing Market by Therapeutic Area
  • 6.1.4: Growth Opportunities for the Global Drug Discovery Outsourcing Market by End Use
  • 6.1.5: Growth Opportunities for the Global Drug Discovery Outsourcing Market by Region
• 6.2: Emerging Trends in the Global Drug Discovery Outsourcing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Drug Discovery Outsourcing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Drug Discovery Outsourcing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Albany Molecular Research
• 7.2: EVOTEC
• 7.3: GenScript
• 7.4: Pharmaceutical Product Development
• 7.5: Charles River
• 7.6: WuXi AppTec
• 7.7: Merck & Co
• 7.8: Thermo Fisher Scientific
• 7.9: Dalton Pharma Services
• 7.10: Oncodesign